Breast Cancer Gene Signature Assay
Identifies patients’ 10 years risk of breast cancer recurrence

FDA approved; CAP & CLIA accredited test.
This gene signature assay is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II) or node-positive
(Stage II or III) early-stage breast cancer to be treated with adjuvant endocrine therapy. It is powered by nCounter digital technology.
Test used to predict patient’s Risk of Recurrence(ROR).
Test included in international clinical practice guidelines.
For more information :
Please refer https://www.oncocyte.com/ or please contact your local sales representative or
Email us at info@sayretherapeutics.com